Ligand Pharmaceuticals LGND Teriparatide injection — Total revenues and income
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's teriparatide injection — total revenues and income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's teriparatide injection — total revenues and income?
- Ligand Pharmaceuticals (LGND) reported teriparatide injection — total revenues and income of $1.32M in Q1 2026.
- How has Ligand Pharmaceuticals's teriparatide injection — total revenues and income changed year-over-year?
- Ligand Pharmaceuticals's teriparatide injection — total revenues and income increased by 10.9% year-over-year, from $1.19M to $1.32M.
- What does teriparatide injection — total revenues and income mean?
- This metric represents the aggregate financial inflows generated by the Teriparatide injection product line, including royalties, milestone payments, and licensing fees. It serves as a key indicator of the commercial performance and market adoption of this specific therapeutic asset within the company's portfolio. Monitoring this figure helps investors assess the contribution of individual licensed products to the company's overall top-line growth.